New Research Suggests Popular Weight-Loss and Diabetes Drugs May Be Linked to Reduced Violent Behavior

The burgeoning popularity of GLP-1 receptor agonists, medications like Ozempic and Wegovy, initially celebrated for their efficacy in weight management and diabetes control, is now the subject of novel scientific…

NIH Researchers Unravel Intricate Brain Cell Signaling of GLP-1 Weight Loss Drugs, Offering Clues to Efficacy and Durability

Researchers at the National Institutes of Health (NIH) have made significant strides in understanding the intricate cellular mechanisms by which GLP-1 weight loss drugs, such as semaglutide, exert their effects…

The Ozempic Era: Fashion Grapples with "Size Volatility" as GLP-1 Drugs Reshape Consumer Bodies and Supply Chains

The burgeoning popularity of Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly known by brand names like Ozempic and Wegovy, is presenting a profound and evolving challenge to the global fashion industry.…

Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs

A comprehensive analysis of federal data spanning a decade has revealed a stark divergence in how different illicit substances correlate with criminal activity and law enforcement intervention. The study, published…

A Major Cochrane Review Casts Doubt on the Efficacy and Safety of Amyloid-Targeting Alzheimer’s Drugs

A comprehensive analysis of 17 clinical trials involving over 20,000 participants has concluded that drugs designed to target amyloid beta proteins in the brain are unlikely to offer significant clinical…

The Promise and Peril of Anti-Amyloid Drugs for Alzheimer’s Disease: A Landmark Review Casts Doubt on Clinical Efficacy and Highlights Safety Concerns

A comprehensive and influential Cochrane review has delivered a significant blow to the long-held therapeutic strategy targeting amyloid beta proteins in the brain for Alzheimer’s disease, concluding that these drugs…